NZ590995A - Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer) - Google Patents

Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer)

Info

Publication number
NZ590995A
NZ590995A NZ590995A NZ59099509A NZ590995A NZ 590995 A NZ590995 A NZ 590995A NZ 590995 A NZ590995 A NZ 590995A NZ 59099509 A NZ59099509 A NZ 59099509A NZ 590995 A NZ590995 A NZ 590995A
Authority
NZ
New Zealand
Prior art keywords
differentiation
cancer
cell growth
abnormal cell
analogs
Prior art date
Application number
NZ590995A
Other languages
English (en)
Inventor
Frank Walter Waligora
John C Amedio Jr
Original Assignee
Ziopharm Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziopharm Oncology Inc filed Critical Ziopharm Oncology Inc
Priority to NZ60113909A priority Critical patent/NZ601139A/en
Priority to NZ60380109A priority patent/NZ603801A/en
Publication of NZ590995A publication Critical patent/NZ590995A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/222Amides of phosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/664Amides of phosphorus acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/14Esters of phosphoric acids containing P(=O)-halide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/14Esters of phosphoric acids containing P(=O)-halide groups
    • C07F9/1406Esters of phosphoric acids containing P(=O)-halide groups containing the structure Hal-P(=O)-O-aryl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/16Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165Esters of thiophosphoric acids
    • C07F9/20Esters of thiophosphoric acids containing P-halide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2429Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ590995A 2008-07-31 2009-07-30 Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer) NZ590995A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ60113909A NZ601139A (en) 2008-07-31 2009-07-30 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
NZ60380109A NZ603801A (en) 2008-07-31 2009-07-30 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13753808P 2008-07-31 2008-07-31
PCT/US2009/052295 WO2010014841A1 (en) 2008-07-31 2009-07-30 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof

Publications (1)

Publication Number Publication Date
NZ590995A true NZ590995A (en) 2012-12-21

Family

ID=41610732

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ60113909A NZ601139A (en) 2008-07-31 2009-07-30 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
NZ60380109A NZ603801A (en) 2008-07-31 2009-07-30 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
NZ590995A NZ590995A (en) 2008-07-31 2009-07-30 Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ60113909A NZ601139A (en) 2008-07-31 2009-07-30 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
NZ60380109A NZ603801A (en) 2008-07-31 2009-07-30 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof

Country Status (16)

Country Link
US (4) US8664201B2 (es)
EP (1) EP2318013A4 (es)
JP (2) JP5711660B2 (es)
KR (1) KR20110038696A (es)
CN (2) CN102137674A (es)
AU (1) AU2009276512B2 (es)
BR (1) BRPI0916739A2 (es)
CA (1) CA2732290A1 (es)
EA (1) EA022655B1 (es)
IL (1) IL210921A (es)
MX (1) MX2011001122A (es)
NZ (3) NZ601139A (es)
SG (2) SG10201600595PA (es)
TW (1) TWI454266B (es)
WO (1) WO2010014841A1 (es)
ZA (1) ZA201100878B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589418A (en) * 2004-10-25 2012-03-30 Dekk Tec Inc Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US8888713B2 (en) 2007-03-07 2014-11-18 Becton, Dickinson And Company Safety blood collection assembly with indicator
EP3100680B1 (en) 2007-03-07 2022-11-23 Becton, Dickinson and Company Safety blood collection assembly with indicator
US8603009B2 (en) 2008-03-07 2013-12-10 Becton, Dickinson And Company Flashback blood collection needle
CA2732290A1 (en) 2008-07-31 2010-02-04 Ziopharm Oncology, Inc. Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
CN102924507A (zh) * 2011-11-10 2013-02-13 安徽四维药业有限公司 一种抗肿瘤化合物及其制备方法与应用、药物组合物
WO2013116281A1 (en) * 2012-01-31 2013-08-08 Ziopharm Oncology, Inc. Combination therapy including isophosphoramide mustard, analogs, or salts thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU427945A1 (ru) * 1972-07-24 1974-05-15 Институт элементоорганических соединений СПОСОБ ПОЛУЧЕНИЯа ПОЛИФТОРАЛКИЛЗАМЕЩЕННЫХБЕНЗИЛДИХЛОРФОСФАТОВ
ATE181551T1 (de) 1992-04-17 1999-07-15 Abbott Lab Taxol-derivate
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
EP1185276B1 (en) 1999-05-24 2003-12-10 Southern Research Institute Isophosphoramide mustard analogs and use thereof
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
NZ589418A (en) * 2004-10-25 2012-03-30 Dekk Tec Inc Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
EP2581367B1 (en) * 2007-04-06 2015-12-30 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof
CA2732290A1 (en) 2008-07-31 2010-02-04 Ziopharm Oncology, Inc. Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof

Also Published As

Publication number Publication date
JP5711660B2 (ja) 2015-05-07
AU2009276512A1 (en) 2010-02-04
CN102137674A (zh) 2011-07-27
MX2011001122A (es) 2011-03-29
JP2014114304A (ja) 2014-06-26
JP2011529907A (ja) 2011-12-15
US20140378704A1 (en) 2014-12-25
EA201170277A1 (ru) 2011-08-30
TWI454266B (zh) 2014-10-01
EA022655B1 (ru) 2016-02-29
EP2318013A1 (en) 2011-05-11
NZ601139A (en) 2014-02-28
NZ603801A (en) 2014-01-31
WO2010014841A1 (en) 2010-02-04
US8664201B2 (en) 2014-03-04
US9254298B2 (en) 2016-02-09
US20150328238A1 (en) 2015-11-19
CA2732290A1 (en) 2010-02-04
ZA201100878B (en) 2011-10-26
US20110212921A1 (en) 2011-09-01
SG183657A1 (en) 2012-09-27
EP2318013A4 (en) 2013-07-24
WO2010014841A8 (en) 2011-02-17
CN104490900A (zh) 2015-04-08
US9145431B2 (en) 2015-09-29
BRPI0916739A2 (pt) 2015-11-03
JP5769831B2 (ja) 2015-08-26
AU2009276512B2 (en) 2014-12-18
IL210921A0 (en) 2011-04-28
IL210921A (en) 2016-04-21
SG10201600595PA (en) 2016-02-26
TW201004631A (en) 2010-02-01
KR20110038696A (ko) 2011-04-14
US20160215005A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
UA105911C2 (uk) Сульфонамідні похідні
NZ590995A (en) Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer)
MX2010008921A (es) Derivados de oxazolidinona.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
IN2012DN01233A (es)
MX2009011816A (es) Derivados de piridina.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX2011011136A (es) Eteres diarilicos.
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2011012122A (es) Derivados de tiofeno.
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY176944A (en) Substituted pyrimidines for the treatment of diseases such as cancer
MY155570A (en) 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
GB0722077D0 (en) Compounds
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2009013501A (es) Compuestos piperidinicos y sus usos.
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JUL 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130504

LAPS Patent lapsed